Zhai Q, Wang X, Chen C, et al
Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), extracellular signal-related kinase (ERK)1/2, and cAMP/protein kinase A (PKA) signaling pathways involving beta-catenin
Facilities and amenities vary by PL
Accessed 10 June 2026
Report any suspected side effects to medicines via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or via the Yellow Card app
For Canadians dealing with metabolic syndrome, prediabetes, or elevated cardiovascular risk markers, the possibility of targeted visceral fat reduction adds a health dimension beyond cosmetic weight loss